Skip to main content

Table 3 Multivariate Cox regression analysis of demo-clinical characteristics predictive for disease specific survival of patients with hepatocellular carcinoma by stage

From: Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database

 

Overall

 

Localized stage

Regional stage

 

Distant stage

 
 

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

Year of diagnosis

 1998–2002

Ref

 

Ref

 

Ref

 

Ref

 

 2003–2007

0.93 (0.88–0.98)

0.003

0.89 (0.83–0.96)

0.001

0.98 (0.91–1.07)

0.71

1.11 (0.93–1.33)

0.24

 2008–2012

0.80 (0.76–0.84)

< 0.001

0.74 (0.69–0.79)

< 0.001

0.86 (0.79–0.93)

< 0.001

1.11 (0.93–1.32)

0.24

 2013–2015

0.75 (0.71–0.79)

< 0.001

0.63 (0.59–0.68)

< 0.001

0.84 (0.77–0.91)

< 0.001

1.12 (0.94–1.34)

0.22

Age in groups (years)

 18–44

Ref

 

Ref

 

Ref

 

Ref

 

 45–54

1.17 (1.08–1.26)

< 0.001

1.31 (1.16–1.49)

< 0.001

1.07 (0.95–1.20)

0.29

1.11 (0.95–1.31)

0.19

 55–64

1.14 (1.06–1.23)

< 0.001

1.31 (1.15–1.48)

< 0.001

1.01 (0.90–1.13)

0.91

1.08 (0.92–1.26)

0.35

 65–74

1.27 (1.17–1.37)

< 0.001

1.56 (1.38–1.77)

< 0.001

1.07 (0.96–1.21)

0.24

1.09 (0.93–1.28)

0.27

  ≥ 75

1.53 (1.41–1.65)

< 0.001

1.96 (1.72–2.22)

< 0.001

1.25 (1.11–1.41)

< 0.001

1.19 (1.01–1.40)

0.04

Sex

 Female vs. male

0.94 (0.91–0.97)

< 0.001

0.93 (0.89–0.98)

0.002

*

 

*

 

Race

 White

Ref

 

Ref

 

Ref

 

*

 

 Black

1.04 (0.99–1.08)

0.07

1.06 (1.00–1.13)

0.04

1.04 (0.98–1.10)

0.23

*

 

 Other

0.81 (0.78–0.84)

< 0.001

0.74 (0.70–0.77)

< 0.001

0.84 (0.79–0.89)

< 0.001

*

 

Ethnicity

 Hispanic vs. non-Hispanic

0.96 (0.93–0.99)

0.02

*

 

0.93 (0.88–0.98)

0.009

*

 

Marital status

 Married vs. not married

0.88 (0.86–0.91)

< 0.001

0.84 (0.81–0.87)

< 0.001

0.94 (0.90–0.98)

0.003

0.92 (0.86–0.97)

0.005

SEER stage

 Localized

Ref

 

*

 

*

 

*

 

 Regional

1.48 (1.43–1.55)

< 0.001

*

 

*

 

*

 

 Distant

2.54 (2.42–2.66)

< 0.001

*

 

*

 

*

 

Tumor size (cm)

  ≤ 2

Ref

 

Ref

 

Ref

 

Ref

 

 2–5

1.50 (1.42–1.57)

< 0.001

1.59 (1.49–1.69)

< 0.001

1.41 (1.28–1.55)

< 0.001

0.96 (0.83–1.11)

0.57

  > 5

2.51 (2.39–2.64)

< 0.001

2.81 (2.64–3.00)

< 0.001

2.39 (2.18–2.62)

< 0.001

1.18 (1.03–1.35)

0.021

Tumor extent

 Single lesion w/o vascular invasion

Ref

 

Ref

 

Ref

 

Ref

 

 Multiple lesions w/o vascular invasion

1.36 (1.31–1.42)

< 0.001

1.44 (1.38–1.50)

< 0.001

1.13 (0.96–1.33)

0.15

1.09 (0.97–1.22)

0.17

 Lesion(s) w/vascular invasion

1.31 (1.26–1.36)

< 0.001

1.27 (1.21–1.35)

< 0.001

1.42 (1.31–1.54)

< 0.001

1.23 (1.13–1.33)

< 0.001

Lymph node involvement

 Yes vs. No

1.14 (1.09–1.20)

< 0.001

*

 

1.30 (1.22–1.38)

< 0.001

*

 

Surgery

 No surgery performed

Ref

 

Ref

 

Ref

 

Ref

 

 Liver-directed therapy

0.54 (0.52–0.56)

< 0.001

0.56 (0.53–0.59)

< 0.001

0.52 (0.48–0.56)

< 0.001

0.41 (0.33–0.51)

< 0.001

 hepatic resection/lobectomy

0.35 (0.33–0.37)

< 0.001

0.34 (0.32–0.36)

< 0.001

0.38 (0.35–0.41)

< 0.001

0.35 (0.29–0.41)

< 0.001

 Hepatectomy with transplant

0.14 (0.13–0.15)

< 0.001

0.14 (0.12–0.15)

< 0.001

0.14 (0.12–0.16)

< 0.001

0.33 (0.21–0.51)

< 0.001

  1. *not included in multivariate model
  2. Abbreviation: HR, hazard ratio; CI, confidence interval